Cargando…

Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients

OBJECTIVE: This study aims to analyze whether there are any differences in clinicopathological features and prognosis between HER2 ultra-low, HER2-null, and HER2-low expression in Chinese breast cancer (BC) patients. METHODS: The clinicopathological data of 1363 HER2-negative BC patients were retros...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Zhaoxu, Jia, Huiqing, Zhang, Huina, Chen, Lifang, Zhao, Peng, Zhao, Jing, Fu, Guangming, Xing, Xiaoming, Li, Yujun, Wang, Chengqin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505593/ https://www.ncbi.nlm.nih.gov/pubmed/37639064 http://dx.doi.org/10.1007/s10549-023-07079-8

Ejemplares similares

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
por: Kurozumi, Sasagu, et al.
Publicado: (2016)

Improving HER2 testing reproducibility in HER2-low breast cancer
por: Sajjadi, Elham, et al.
Publicado: (2022)

HER2/positive and HER2/low in inflammatory breast cancer recurrence
por: Movchan, Oleksii Volodimirovich, et al.
Publicado: (2022)

Current Biological, Pathological and Clinical Landscape of HER2-Low Breast Cancer
por: Zhang, Huina, et al.
Publicado: (2022)

Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
por: Agersborg, Sally, et al.
Publicado: (2018)

Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
por: Tarantino, P., et al.
Publicado: (2023)

Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens
por: Moy, Beverly, et al.
Publicado: (2021)

HER2-targeted therapy influences CTC status in metastatic breast cancer
por: Deutsch, Thomas M., et al.
Publicado: (2020)

Prognostic values of clinical and molecular features in HER2 low-breast cancer with hormonal receptor overexpression: features of HER2-low breast cancer
por: Chen, Mengdi, et al.
Publicado: (2022)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Can HER2 1+ Breast Cancer Be Considered as HER2-Low Tumor? A Comparison of Clinicopathological Features, Quantitative HER2 mRNA Levels, and Prognosis among HER2-Negative Breast Cancer
por: Shu, Lan, et al.
Publicado: (2022)

EndoPredict(®) in early hormone receptor-positive, HER2-negative breast cancer
por: Almstedt, K., et al.
Publicado: (2020)

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study
por: Lynce, F., et al.
Publicado: (2019)

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
por: Wang, Wei, et al.
Publicado: (2022)

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
por: Venetis, Konstantinos, et al.
Publicado: (2022)

Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis
por: Moss, Nelson S., et al.
Publicado: (2023)

Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population
por: Chen, Ruixian, et al.
Publicado: (2022)

Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital
por: Cunningham, Niamh, et al.
Publicado: (2022)

Can Patients with HER2-Low Breast Cancer Benefit from Anti-HER2 Therapies? A Review
por: Wang, Jin, et al.
Publicado: (2023)

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
por: Cai, Mengyuan, et al.
Publicado: (2023)

Clinical characteristics, tumor‐infiltrating lymphocytes, and prognosis in HER2‐low breast cancer: A comparison study with HER2‐zero and HER2‐positive disease
por: Lu, Yujie, et al.
Publicado: (2023)

Everolimus plus exemestane as first-line therapy in HR(+), HER2(−) advanced breast cancer in BOLERO-2
por: Beck, J. Thaddeus, et al.
Publicado: (2013)

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
por: Agostinetto, Elisa, et al.
Publicado: (2021)

The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer
por: Bardia, Aditya, et al.
Publicado: (2022)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
por: van den Ende, Nadine S., et al.
Publicado: (2022)

Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
por: Zhou, Shuling, et al.
Publicado: (2022)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer
por: Yu, Y. F., et al.
Publicado: (2017)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

The Exciting New Field of HER2-Low Breast Cancer Treatment
por: Eiger, Daniel, et al.
Publicado: (2021)

Refining the definition of HER2‐low class in invasive breast cancer
por: Atallah, Nehal M, et al.
Publicado: (2022)

How I treat HER2-low advanced breast cancer
por: Schlam, Ilana, et al.
Publicado: (2023)

HER2-Low Breast Cancer: Current Landscape and Future Prospects
por: Shirman, Yelena, et al.
Publicado: (2023)

Clinicopathological features and prognosis of patients with HER2-low breast cancer
por: Yang, Xin, et al.
Publicado: (2023)

Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer
por: Kim, Yun Gyoung, et al.
Publicado: (2017)

Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
por: Ilie, Silvia Mihaela, et al.
Publicado: (2023)

Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
por: Stenehjem, David D, et al.
Publicado: (2014)

Clinicopathological characteristics and prognostic analysis of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS) and DCIS with microinvasion (DCIS-Mi) of the breast
por: Jia, Huiqing, et al.
Publicado: (2022)

The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
por: Lemieux, J., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_2rr3vfvl4e0bv2a2i1gg9ht1bt